Articles

Modifying ADAMTS13 to modulate binding of pathogenic autoantibodies of patients with acquired thrombotic thrombocytopenic purpura

Icosagen Cell Factory OÜ, Össu, Kambja, Tartumaa, Estonia;
Department of Molecular and Cellular Hemostasis, Sanquin-Academic Medical Center, The Netherlands;
Laboratory for Thrombosis Research, IRF Life Sciences, KU, Leuven Campus Kulak Kortrijk, Belgium;
Laboratory for Thrombosis Research, IRF Life Sciences, KU, Leuven Campus Kulak Kortrijk, Belgium;
Department of Molecular and Cellular Hemostasis, Sanquin-Academic Medical Center, The Netherlands;
Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), The Netherlands;
Groupe Hospitalier Saint Louis-Lariboisiere, AP-HP, Université Paris Diderot, Paris, France;
Service Hematologie, Hôpital Saint-Antoine, AP-HP, Paris, France
Laboratory for Thrombosis Research, IRF Life Sciences, KU, Leuven Campus Kulak Kortrijk, Belgium;
Icosagen Cell Factory OÜ, Össu, Kambja, Tartumaa, Estonia;
Department of Molecular and Cellular Hemostasis, Sanquin-Academic Medical Center, The Netherlands;
Haematologica Early view Nov 21, 2019 https://doi.org/10.3324/haematol.2019.226068